• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

The recommendations listed in this guideline are, whenever possible, evidence based. An
initial extensive evidence review, which included literature derived from research involving …

Aim This executive summary of the hypertrophic cardiomyopathy clinical practice guideline
provides recommendations and algorithms for clinicians to diagnose and manage …

This international multidisciplinary document intends to provide clinicians with evidence-
based practical patient-centered recommendations for evaluating patients and decedents …

Arrhythmogenic cardiomyopathy (ACM) is an arrhythmogenic disorder of the myocardium
not secondary to ischemic, hypertensive, or valvular heart disease. ACM incorporates a …

This international consensus statement is the collaborative effort of three medical societies
representing electrophysiology in North America, Europe and Asian-Pacific area: the Heart …

HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients
with inherited primary arrhythmia syndromes | EP Europace | Oxford Academic Skip to Main …

Hypertrophic cardiomyopathy (HCM) is the most common familial heart disease with vast
genetic heterogeneity, demonstrated over the past 20 years. Mutations in 11 or more genes …

The sudden death of a young, apparently fit and healthy person is amongst the most
challenging scenarios in clinical medicine. Sudden cardiac death (SCD) is a devastating …

Background—Yield of causative variants in hypertrophic cardiomyopathy (HCM) is
increased in some probands, suggesting different clinical subgroups of disease occur. We …